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ABSTRACT  
 
Sensory peripheral neuropathy (PN) remains a common complication in HIV-positive patients despite 
effective combination anti-retroviral therapy (ART). Data on PN on second-line ART is scarce. We 
assessed PN using a standard tool in patients failing first-line ART and for 96 weeks following a 
switch to PI-based second-line ART in a large Randomised Clinical Trial in Sub-Saharan Africa. Factors 
associated with PN were investigated using logistic regression. Symptomatic PN (SPN) prevalence 
was 22% at entry (N=1251) and was associated (p<0.05) with older age (OR=1.04 per year), female 
gender (OR=1.64), Tuberculosis (TB) (OR=1.86), smoking (OR=1.60), higher plasma creatinine 
(OR=1.09 per 0.1mg/dl increase), CD4 count (OR=0.83 per doubling) and not consuming alcohol 
(OR=0.55). SPN prevalence decreased to 17% by week 96 (p=0.0002) following similar trends in all 
study groups (p=0.30). Asymptomatic PN (APN) increased over the same period from 21% to 29% 
(p=0.0002). Signs suggestive of PN (regardless of symptoms) returned to baseline levels by week 96. 
At weeks 48 and 96, after adjusting for time-updated associations above and baseline CD4 count and 
viral load, SPN was strongly associated with TB (p<0.0001). In summary, SPN prevalence was 
significantly reduced with PI-based second-line therapy across all treatment groups, but we did not 
find any advantage to the NRTI-free regimens.  The increase of APN and stability of PN-signs 
regardless of symptoms suggest an underlying trend of neuropathy progression that may be masked 
by reduction of symptoms accompanying general health improvement induced by second-line ART.  
SPN was strongly associated with isoniazid given for TB treatment. 
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INTRODUCTION 
Sensory peripheral neuropathy (PN) remains one of the most common complications in HIV-positive 
patients despite the use of effective combination anti-retroviral therapy (cART)(Ellis et al., 2010; 
Kamerman, Wadley, & Cherry, 2012). Prevalence of symptomatic PN in HIV-positive individuals has 
been reported to range between 20–60% in cross-sectional studies and has been associated with 
several factors. PN is a complication of HIV disease progression in ART-naïve patients but can also be 
aggravated by ART-induced immune restoration, where greater CD4 cell count recovery has been 
associated with an increased risk of developing PN(Childs et al., 1999; Ellis et al., 2010; Maritz et al., 
2010). However, more often it has been reported as adverse reaction to dideoxynucleosides or “d-
drugs”, particularly stavudine (d4T) and didanosine (ddI)(van Oosterhout et al., 2012; Wadley, 
Cherry, Price, & Kamerman, 2011; Wright et al., 2008) which until relatively recently were frequently 
used in Sub-Saharan African countries. Other drugs frequently used in HIV-positive individuals such 
as isoniazid  can also cause similar neuropathic symptoms(van der Watt, Harrison, Benatar, & 
Heckmann, 2011). Clinical presentation of HIV-induced and toxicity-associated PN are often 
indistinguishable and regardless of its cause PN has a significant negative impact on the quality of 
life of HIV-positive adults(Biraguma & Rhoda, 2012; Ellis et al., 2010).  
 
In ART-naïve patients, signs of PN appear to persist after initiation of effective cART and increase 
over-time(D. Evans, Takuva, Rassool, Firnhaber, & Maskew, 2012; S. R. Evans et al., 2011). Incidence 
of new PN while on first-line cART has been estimated to range between 12 to 21 cases per 100 
person-years but association between “d-drug” exposure and persistent or incident PN during first-
line therapy has been inconsistently reported(S. R. Evans et al., 2011; Mehta et al., 2011; Nakamoto 
et al., 2010). In ART-experienced patients PN appears to remain a major problem despite effective 
virological control(Chen et al., 2013b). Little is known about prevalence of and risk factors for PN in 
ART-experienced patients failing first-line ART or how PN changes on protease inhibitor (PI)-based 
second-line ART in resource-limited settings. We therefore conducted an analysis to investigate this 
in a large clinical trial in sub-Saharan Africa.  
 
METHODS  
Participants and setting 
The EARNEST trial was a large, open-label, randomised clinical trial (ISRCTN-37737787), performed in 
14 centres in sub-Saharan Africa where HIV-positive adult and adolescent patients with virological, 
immunological or clinical first-line cART failure were randomised to lopinavir/ritonavir 
400mg/100mg twice daily with either (i) 2-3 new or recycled NRTIs chosen by the treating physician 
(“PI/NRTI”); (ii) raltegravir 400mg twice daily (“PI/RAL”); or (iii) raltegravir induction for the first 12 
weeks only (“PImono”). The main analysis of the trial has been reported elsewhere(Paton et al., 
2014). In summary, the PI/NRTI arm and PI/RAL arm were indistinguishable on the primary 
composite endpoint (clinical, immunological and virological components) and produced identical 
rates of VL suppression at 96 weeks (86% <400 copies/ml). The PI-mono arm was similar to PI/NRTI 
on clinical and CD4 components of the composite endpoint, but VL suppression was substantially 
worse (61% <400 copies at 96 weeks). The study (which included neuropathy assessments as part of 
the main protocol in all patients) was approved by all relevant ethics committees and regulatory 
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agencies in participating countries and in the UK. All participants or caregivers provided written 
informed consent. 
 
Participants were assessed for PN using the AIDS Clinical Trials Group (ACTG) Brief Peripheral 
Neuropathy Screen tool (BPNS)(Cettomai et al., 2010; Marra, Boutin, & Collier, 1998) at baseline, 
week 48 and week 96. Symptomatic PN (SPN) was defined as presence of bilateral neuropathic 
symptoms (at least one of pain, aching or burning, pins and needles, or numbness) and abnormal 
signs (either reduced or absent ankle reflex or reduced vibration sense at the great toe (vibration of 
a 128-Hz tuning fork felt for 10 seconds or less))(Ellis et al., 2005; S. R. Evans et al., 2011). 
Asymptomatic PN (APN) was defined as reduced or absent ankle reflex or reduced vibration sense at 
the great toe without symptoms. Site investigators were trained on the BPNS tool at site initiation 
visits.  
 
In addition, medical assessment at these study visits included symptom review, physical 
examination, full blood count, serum creatinine levels and CD4 counts. HIV-RNA was measured 
centrally (Joint Clinical Research Centre, Kampala, Uganda) on stored plasma samples. 
 
Statistical analysis 
All statistical tests presented are two-sided. All analyses were carried out in Stata version 13.1. 
Association between PN and patient characteristics at switch to second-line, including 
demographics, study site, anthropometric measures, CD4 cell count, HIV-RNA level, WHO HIV 
disease stage, ART exposure, co-morbidities (such as TB, diabetes mellitus, and cardiovascular 
disease(CVD)), concomitant medication in the last 10 weeks, alcohol consumption, smoking status, 
and socio-economic variables including household income and employment status were modelled 
using complete case univariable logistic regression with fractional polynomials to allow for non-
linear relationships between continuous factors and PN. Years on first-line ART and creatinine were 
censored at approximate 99th percentiles to reduce the impact of outliers. Centre effects were 
estimated pooling sites with similar overall prevalence (Table 1) to prevent perfect prediction in low 
prevalence sites. Primary analyses excluded 19 participants from the smallest centre that reported 
very high and potentially implausible rates of PN on symptom report (12/19 63%) and abnormal 
signs (17/17 with completed PN signs, 100%). 
Factors associated with PN status univariably with P<0.2 were included in a multivariable logistic 
regression. Backward selection (exit criteria P>0.1) was used to select independent risk factors using 
fractional polynomials to allow for non-linear relationships (Stata mfpmi command). Multiple 
imputation using chained estimating equations (Stata ice command) was used to impute a small 
amount of missing data in risk factors and components of PN (if at least one component was 
complete)(van Buuren, Boshuizen, & Knook, 1999).  
Sensitivity analyses were performed (i) on complete cases, (ii) using multiple imputation including 
the site excluded from the primary analysis, and (iii) abnormal signs (regardless of the presence of 
symptoms) (iv) symptoms (regardless of the presence of abnormal signs), and (v) bilateral symptoms 
plus either reduced vibration sense or absent ankle reflex. A repeated measures model (generalized 
estimating equations, independent correlation structure, binomial distribution) looked at the effect 
of time updated factors selected in the baseline model as well as baseline CD4 and viral load on PN 
at weeks 48 and 96 in complete cases. 
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Prevalence of SPN, APN, abnormal signs (regardless of the presence of symptoms), and symptoms 
(regardless of the presence of abnormal signs) were calculated at baseline, week 48 and 96 by study 
treatment arm in those with complete PN assessment and was compared between the arms at each 
time point using risk differences and chi squared tests. Generalised estimating equations 
(independent correlation structure, binomial distribution) were used to test for a difference 
between the arms across all time points. 
 
RESULTS  
 
Of the 1277 patients randomised in the EARNEST trial, 19 were from the excluded site, 1 had 
completely absent baseline PN assessment, and 1 was an amputee so could not be assessed leaving 
1256 (98%) eligible patients. 1251 had a complete PN assessment at baseline. Of these, 726 (58%) 
were female and the median age at switch to second-line was 37 years (inter-quartile range (IQR) 
31-44). At second-line switch, patients had been on first-line cART for a median of 4 years (IQR 2.8-
5.4); most had been exposed to zidovudine (AZT) (68%) or d4T (60%) during first-line, with fewer 
already exposed to tenofovir disoproxil fumarate (TDF) (14%). At switch, median CD4 count was 71 
cell/mm3 (IQR 30-147), median plasma HIV viral load (VL) was 67500 copies/ml (IQR 22818–193000) 
and 80% of participants with medical history available had been reported to have at least one WHO 
stage 3/4 condition (Table 1). In EARNEST 420 participants were randomised to PI/NRTI (TDF in 79%, 
abacavir (ABC) in 16%, ddI in 13%, d4T in <1%, lamivudine/emtricitabine (3TC/FTC) in 87%), 422 to 
PI/RAL and 409 PImono second-line ART.  
 
 
PN at first-line failure:  
 
At switch, 279 of the 1251 (22%) patients with a complete PN assessment met the study definition 
for SPN and  the prevalence of APN was similar at 21%. Overall 44% of patients had abnormal signs 
at examination. SPN prevalence differed significantly between study sites ranging from 0 to 44% 
(P<0.0001). However, prevalence of SPN in the three Kampala sites was remarkably similar (25-28%) 
whereas the other six Ugandan sites, located elsewhere in the country, showed also similar but 
much lower prevalence (0-9%).  
 
The characteristics of the patients at first line failure and the univariable associations with SPN are 
shown in Table 1. In the multivariable model, independent associations were found with age, female 
gender, history of TB, and higher levels of plasma creatinine. The odds of having PN at first line 
failure were lower with higher CD4 counts and alcohol consumption, whereas smokers were more 
likely to have SPN at entry (Table 2). Weak evidence (0.05<p<0.1) of associations with increasing risk 
of SPN were found with viral load, increasing glucose, family history of CVD, TDF or nevirapine (NVP) 
during first-line, and employment status. 
 
An exploratory analysis considered additional impact on SPN of exposure to d4T and time on d4T. 
After adjusting for the factors above, d4T at any time on first-line (ignoring duration) was not 
independently associated with SPN (p=0.44), however adjusting for duration of exposure suggested 
SPN risk was higher in those with a short exposure, with the risk decreasing with increasing time on 
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d4T (p=0.007) (supplementary material table 3). When isoniazid use in the last 10 weeks was 
included in the model as well as TB these were not independently associated with SPN, and TB was 
the better predictor of SPN. When substituting TB with isoniazid, the effect of isoniazid was 
comparable to TB (supplementary material table 4).   
 
Sensitivity analyses that included complete cases, the excluded site, bilateral symptoms and reduced 
vibration sense or absent ankle reflex, and presence of symptoms gave results similar to those 
above. There was no evidence of an association between abnormal signs (regardless of symptoms) 
and sex, TDF exposure, or alcohol. Effects were attenuated compared to the SPN model for VL, CD4, 
NVP exposure, smoking, family history of CVD, and glucose. The effect of age, TB, creatinine, and 
employment status remained unchanged and additional associations were identified with d4T 
(OR=1.44; 95% CI 1.02-2.05; p=0.04), and height (OR=1.03; 95% CI 1.01-1.05; p=0.001). 
(supplementary material table 5). 
 
PN on second-line therapy: 
 
Overall, 135 out of 1176 (11%) patients assessed at week 48 had SPN (P<0.0001 vs baseline) whereas 
the prevalence at week 96 was 17% (P<0.0001 vs week 48, p=0.0002 vs baseline) (Figure 1(a)). In 
contrast, the prevalence of APN showed a steady increase over time (21%, 24% and 29% at weeks 0, 
48, 96 respectively; trend p=0.0002) (figure 1b). Abnormal signs suggestive of PN had a smaller 
decline in prevalence at week 48 than SPN (44%, 36% at weeks 0, 48 respectively) but returned to 
baseline levels by week 96 (46%) (Figure 1c).   
 
As expected, the prevalence of SPN was similar between study groups at entry (23%, 23% and 22% in 
PI/NRTI, PI/RAL and PImono respectively). There was no difference in SPN prevalence between 
randomisation arms at week 96 (global p=0.11) (Table 3). Overall, there was no evidence for 
differences between study group in the trends over time of any PN outcome measure (p>0.1, Figure 
1). At week 48 and 96 there was no effect of baseline or current VL, current CD4, smoking, alcohol 
consumption, or creatinine. The effect of family history of CVD, glucose at failure, sex, NVP and TDF 
exposure was attenuated, and baseline CD4, age, TB and job status remained unchanged 
(Supplementary Table 10). Similarly to baseline, isoniazid and TB were not independently associated 
with PN and isoniazid remained strongly associated with SPN (p<0.0001) after adjusting for the 
factors above. 
 
Considering the 1132 participants with PN status assessed at all time-points, the rate of incident SPN 
was 4% (38/882 patients with no SPN at baseline) by week 48 and 9% (75/844 patients without SPN 
at week 48) by week 96  (Figure 2). Resolution of SPN was observed in 64% (159/250) of patients 
with SPN at baseline by week 48 and 31% (28/91) of patients with persistent SPN at week 48 by 
week 96. Overall, 58% (145/250) of the participants with SPN at first line failure had SPN resolution 
at week 96. Isoniazid-based TB treatment was prescribed during study period to 18% of patients who 
developed incident SPN, but only to 6% of those patients who never developed SPN (P<0.001). 
However, we found no evidence of pyridoxine reducing the chance of developing SPN since 7/18 
(39%) of those given pyridoxine and 13/48 (27%) not given it developed SPN (p=0.35). 
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DISCUSSION  
In this large, well-characterised cohort of patients taking part in a randomised controlled trial on PI-
based second-line ART that were systematically assessed using a well-validated and objective tool, 
we observed a prevalence of SPN of 22% at second-line switch, similar to levels reported in ART-
experienced patients in Sub-Saharan Africa (21%)(Luma et al., 2012; van Oosterhout et al., 2012) but 
lower than the prevalence reported at virological failure in the ALLRT study  in the USA (33.7%)(Chen 
et al., 2013b).  ALLRT study participants were assessed using the same tool but were slightly older 
and had been exposed to ART for longer than those recruited in EARNEST (median (IQR) age at entry 
43 (37-48) and 37 (31-44) years and median (IQR) exposure to ART prior entry 6.0 (3.0, 9.3) and 4.0 
(2.8-5.4)years respectively) which at least partially explains the differences in SPN prevalence given 
the consistent associations between these factors and increased risk of SPN(Cherry et al., 2009; Ellis 
et al., 2010; S. R. Evans et al., 2011).  
 
We found low CD4 count, but not HIV-VL associated with SPN suggesting that immuno-suppression 
or the incident opportunistic conditions associated with it, and the drugs required for the treatment 
of these conditions is a key predictor(Ellis et al., 2010; Luma et al., 2012). In particular, we found that 
history of TB was independently associated with SPN at the time of first-line failure probably 
reflecting associations between SPN and exposure to anti-TB treatment (Luma et al., 2012; Maritz et 
al., 2010; van der Watt et al., 2011). Neuropathy is a well-known adverse effect attributable to 
isoniazid, although rare when used as preventive therapy(Grant et al., 2010). Pyridoxine co-
administration effectively reduces the risk of developing isoniazid -induced PN but it is inconsistently 
prescribed as part of TB treatment in Sub-Saharan Africa (Grant et al., 2010; van der Watt et al., 
2011). In EARNEST, only 26% of patients were prescribed pyridoxine when treated for incident TB. 
The risk of developing drug-induced PN is independently and significantly higher in patients 
simultaneously exposed to isoniazid and d-drugs(Breen et al., 2006; Dean et al., 2002), but appears 
to peak after the first few months of exposure to these antiretrovirals, and decline 
thereafter(Arenas-Pinto, Bhaskaran, Dunn, & Weller, 2008; Dean et al., 2002; Westreich et al., 2009). 
In our study, adding d4T and duration of exposure to d4T to our final multivariable model similarly 
found that the risk of presenting SPN decreased with duration of exposure to d4T in first-line, 
possibly due to only those not affected by SPN remaining on this NRTI for long periods of time (i.e. 
channelling bias) or due to special  susceptibility, probably genetically mediated, to toxic effects 
induced by d-drugs(Arenas-Pinto et al., 2008; Kampira, Kumwenda, van Oosterhout, & Dandara, 
2013). 
 
Our data do not support associations previously reported between PN and alcohol consumption or 
anthropometric measures(Cherry et al., 2009; Grant et al., 2010; Luma et al., 2012). In our cohort, 
only 10% of participants reported drinking alcohol ever and patients with SPN reported it less often 
than patients without neuropathy (7% vs. 12%; p=0.02). This apparently protective effect of alcohol 
has been previously described in observational studies(Pettersen et al., 2006) and in-vitro data 
suggest that cerebral neurons pre-treated with ethanol were resistant to the neurodegenerative 
effect of HIV protein gp120(Collins, Neafsey, & Zou, 2000).  Alternatively, although the effect of 
alcohol is adjusted for job status, it may be possible that alcohol consumption was associated with 
other socio-economic variables we did not measure. 
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After starting second line therapy, we observed a significant reduction in the prevalence of SPN by 
week 96. However, the prevalence of signs suggestive of PN regardless of symptoms showed a 
smaller (though still significant) decline in response to second line treatment whereas APN actually 
increased progressively during follow up consistent with previous observations(Ellis et al., 2010; S. R. 
Evans et al., 2011). There is likely a complex interplay of factors explaining these changes in second-
line therapy. Firstly, re-establishing VL control, treatment of opportunistic infections and general 
recovery of health might contribute to the initial reduction in symptoms. This decrease in SPN 
prevalence may perhaps be augmented by the confusion of non-neuropathy symptoms with 
neuropathy symptoms due to discrepancies between terms used to describe neuropathic pain in 
local African languages and English(Shaikh, Bentley, & Kamerman, 2013). The cessation of d4T used 
in first-line may also have contributed to some of the symptomatic improvement(S. R. Evans et al., 
2011) although we did not find any advantage to NRTI-free regimens tested in EARNEST (PI/RAL or 
PImono). Most patients in the PI/NRTI group were treated with TDF, which is unlikely to cause PN, 
but some (14%) were exposed to ddI in this group. 
  
Symptom decrease with recovery of health on second line may be masking an underlying trend of 
neuropathy progression.  One additional possibility to consider is that the PI contributed to some of 
the neuropathy progression in second line(Chen et al., 2013a; Pettersen et al., 2006). Although the 
exact mechanism for the association between PI and PN is not known(Ellis et al., 2008; Lichtenstein 
et al., 2005), in-vitro data suggest that exposure to indinavir can induce neuronal degeneration in 
dorsal root ganglion cultures(Pettersen et al., 2006). Furthermore, PI exposure has been associated 
with insulin resistance and development of diabetes mellitus (DM)(Paik & Kotler, 2011) which may 
also lead to PN in both general and HIV-infected populations. However, we did not see any 
association between PN and DM. 
 
Limitations of this study include the limited information available on past medical history and the 
use of non-ART medication prior to study entry (only medications in the last 10 weeks were 
collected). Clinical assessments in our study were performed by non-neurologists but medically 
qualified investigators using a rigorous case definition based on a tool previously validated in African 
settings(Luma et al., 2012; Maritz et al., 2010; Wadley et al., 2011). There were large differences 
between the sites in prevalence (after adjusting for other associations) that might suggest the 
possibility of systematic differences in the way the tests were applied. However, the fact that the 
prevalence of neuropathy in the three sites in Kampala was remarkably similar (25-28%) whereas the 
other six Ugandan sites, located elsewhere in the country and with differing ethnic groups, also 
showed similar but much lower prevalence (0-9%) provides some support for the belief that these 
differences reflect true population differences rather than erratic application of the tool.   
 
In conclusion, our study provides evidence of high prevalence of SPN in HIV-positive patients from 
Sub-Saharan African countries at the time of first-line failure and during PI-based second-line 
therapy. In addition to well-recognised risk factors such as age, female gender and low CD4 count, 
SPN appeared to be strongly associated with toxic effects of isoniazid used to treat TB episodes, 
highlighting the importance of ensuring that pyridoxine is prescribed with TB treatment. The 
potential contribution to PIs to maintaining the high rate of neuropathy during second line therapy 
and management strategies to treat neuropathy deserve further investigation. 
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Table 1: Characteristics at switch to second-line (baseline) 
    PN no PN Total 
P 
  (N=279) (N=972) (N=1251) 
a
 
Demographic characteristics 
    
Female – n(%) 162 (58%) 564 (58%) 726 (58%) 0.99 
Age - median (IQR) 41 (35-47) 36 (30-43) 37 (31-44) <0.0001 
Height cm - median(IQR) 167 (159-174) 164 (157-171) 164 (158-172) 0.001 
BMI kg/m
2 -  
median (IQR)  20 (18-23) 21 (18-24) 21 (18-23) 0.20 
CD4 cells/mm3 
    
 
median (IQR) 55 (21-113) 76 (33-154) 71 (30-147) <0.0001 
 
<100 197 (71%) 572 (59%) 769 (61%) 
 
Viral load copies/ml 
    
 
Median  81762 64529 67500 0.03 
(IQR) (29442-227600) (21346-178978) (22818-193000) 
 
 
≥100,000 135 (48%) 379 (39%) 514 (41%) 
 
WHO disease stage   
    
 
WHO stage 3/4 condition – 
n/total n(%) 
169/209 (81%) 429/538 (80%) 598/747 (80%) 0.73 
ART history 
    
Years on combination ART 
 
- median 
(IQR) 
4.3 (2.9-5.6) 3.9 (2.7-5.3) 4.0 (2.8-5.4) 0.06 
Ever taken first-line  – n(%) 
    
 
Nevirapine 252 (90%) 823 (85%) 1075 (86%) 0.02 
 
Zidovudine  172 (62%) 682 (70%) 854 (68%) 0.007 
 
Stavudine 199 (71%) 557 (57%) 756 (60%) <0.0001 
 
Tenofovir 31 (11%) 149 (15%) 180 (14%) 0.08 
Laboratory parameters 
    
Haemoglobin g/dL –median (IQR) 11.7 (10.3-13.2)  12.2 (10.9-13.4) 12.1 (10.7-13.4) 0.02 
Fasting glucose mmol/L – median (IQR) 4.6 (4.3-5.0) 4.5 (4.1-4.9) 4.5 (4.2-4.9) 0.01 
Creatinine mg/dL  - median (IQR) 0.8 (0.6-1.0) 0.7 (0.6-0.9) 0.7 (0.6-0.9) <0.0001 
Medical history 
    
Diabetes mellitus – n/total n(%) 7/279 (3%) 15/967 (2%) 22/1246 (2%) 0.29 
Tuberculosis 
 
– n(%) 105 (38%) 225 (23%) 330 (26%) <0.0001 
Cardiovascular disease (CVD) – n/total 
n(%) 
29/279 (10%) 47/971 (5%) 76/1250 (6%) 0.001 
Family history of CVD – n/total n(%) 63/218 (29%) 121/736 (16%) 184/954 (19%) <0.0001 
Alcohol consumption (ever) 
b
 – n/total 
n(%) 
18/269 (7%) 95/823 (12%) 113/1092 (10%) 0.03 
Smoke exposure (ever) 
c
 – n/total n(%) 55/278 (20%) 119/970 (12%) 174/1248 (14%) 0.002 
Concomitant medication (last 10 
weeks)  
    Isoniazid – n(%) 42 (15%) 59 (6%) 101 (8%) <0.0001 
Ethambutol  – n(%) 39 (14%) 54 (6%) 93 (7%) 
<0.00 
01 
Pyrazinamide – n(%) 34 (12%) 46 (5%) 80 (6%) <0.0001 
                                                                                                                                                         
Page 10 of 18 
 
Rifampicin – n(%) 32 (11%) 47 (5%) 79 (6%) <0.0001 
Fluclonazole  – n(%) 25 (9%) 61 (6%) 86 (7%) 0.12 
Ciprofloxacin  – n(%) 15 (5%) 27 (3%) 42 (3%) 0.04 
Cotrimoxazole  – n(%) 256 (92%) 906 (93%) 1162 (93%) 0.41 
Socio-economic factors 
    
Employment status 
    
 
Available 279 967 1246 
 
 
Employed 161 (58%) 624 (65%) 785(63%) 
<0.0001  
Student 2 (1%) 95 (10%) 97 (8%) 
 
Unemployed- ill health 66 (24%) 109 (11%) 175 (14%) 
 
Unemployed- lack of jobs 50 (18%) 139 (14%) 189 (15%) 
Household monthly income  – n(%) 
    
 
Available 238 848 1086 
<0.0001  
<$50 87 (37%) 426 (50%) 513 (47%) 
 
$50-$200 90 (38%) 288 (34%) 378 (35%) 
  ≥$200 61 (26%) 134 (16%) 195 (18%) 
Centre      
 Kampala (JCRC) 60 (22%) 171 (18%) 231 (18%) 
<0.0001 
 Kampala (IDI) 54 (19%) 161 (17%) 215 (17%) 
 Kampala (Nsambya) 13 (5%) 34 (4%) 47 (4%) 
 Zimbabwe 117 (42%) 146 (15%) 263 (21%) 
 Others 
d
 35 (13%) 460 (47%) 495 (40%) 
 All p values from logistic regression. MFP was used for continuous variables to allow of non-linear relationships 
a
 This table includes complete cases. Multivariable analysis is on multiply imputed data so includes an additional 6 participants 
who have missing symptomatic neuropathy status 
 
b
 For model including units, p=0.49 for units of alcohol consumed in a week. 
c
 Only 20 participants currently smoked so current and ex-smoker grouped into ever smokers.  
d
 Site prevalence varies from 0%-11% in 9 sites with 31-97 participants per site. Site geographical locations were rural Uganda, 
Kenya, and Zambia 
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Table 2: Multivariable analysis of factors associated with Symptomatic Peripheral Neuropathy at 
first-line ART failure 
  Unadjusted Odds 
ratio (95% CI)* 
P value Adjusted Odds 
ratio (95% CI) 
P value 
Sex- female 1.00 (0.76, 1.31) 0.99 1.65 (1.13, 2.41) 0.01 
Age -years  1.05 (1.04, 1.06) <0.0001 1.04 (1.02, 1.06) <0.0001 
CD4 (per doubling) 0.82 (0.76, 0.88) <0.0001 0.83 (0.76, 0.92) <0.0001 
TB 2.00 (1.51, 2.66) <0.0001 1.86 (1.33, 2.60) <0.0001 
Smoke exposure (ever) 1.76 (1.24, 2.51) 0.002 1.61 (1.02, 2.53) 0.04 
Alcohol use 0.55 (0.33, 0.93) 0.03 0.54 (0.30, 0.96) 0.04 
Creatinine  (per 0.1mg/dl inc) 1.13 (1.07, 1.18) <0.0001 1.09 (1.03, 1.16) 0.006 
Centre      
 Kampala (JCRC) 1 <0.0001 1 <0.0001 
 Kampala (IDI) 0.96 (0.62, 1.46)  0.82 (0.51, 1.33)  
 Kampala (Nsambya) 1.09 (0.54, 2.20)  1.08 (0.48, 2.39)  
 Zimbabwe 2.28 (1.56, 3.35)  1.07 (0.67, 1.70)  
 Others † 0.22 (0.14, 0.34)  0.20 (0.12, 0.32)  
Viral Load (per doubling) 1.07 (1.00, 1.14) 0.03 1.07 (1.00, 1.15) 0.06 
Glucose (per doubling) 1.63 (1.00, 2.66) 0.05 1.71 (0.96, 3.05) 0.07 
Family history of CVD 2.07 (1.45, 2.94) <0.0001 1.49 (0.98, 2.27) 0.06 
Tenofovir exposure 0.69 (0.46, 1.04) 0.08 0.65 (0.40, 1.06) 0.08 
Nevirapine exposure 1.69 (1.10, 2.61) 0.02 1.56 (0.95, 2.57) 0.08 
Employment status     
 Employed 1 <0.0001 1 0.07 
 Student 0.08 (0.02, 0.33) 0.35 (0.08, 1.53) 
 Unemployed- too ill 2.35 (1.65, 3.33) 1.47 (0.97, 2.23) 
 Unemployed- no jobs 1.39 (0.97, 2.01) 1.37 (0.90, 2.07) 
* contains only variables included in the multivariable model 
† Site prevalence varies from 0%-11% in 9 sites with 31-97 participants per site. Site geographical locations were rural 
Uganda, Kenya, and Zambia 
 
 
Table 3: Symptomatic peripheral neuropathy arm comparison 
  PI/ NRTI PI/ RAL PI mono 
Global p 
value 
PI/RAL vs PI/NRTI PI mono vs PI/NRTI 
 n/total n (%) n/total n (%) n/total n (%) Risk difference 
(95% CI) 
p 
value 
Risk difference 
(95% CI) 
p 
value 
Week 0 96/420(23%) 95/422(23%) 88/409(22%)      
Week 48 38/392(10%) 52/395(13%) 45/389(12%) 0.31 +3.5% (-1.0%, +7.9%) 0.13 +1.9% (-2.4%, +6.2%) 0.40 
Week 96 52/378(14%) 70/389(18%) 73/380(19%) 0.11 +4.2% (-0.9%, +9.4%) 0.11 +5.5% (+0.2%, +10.7%) 0.04 
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Fig. 1 Percentage of Patients with Peripheral Neuropathy during the study period by treatment arm
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Fig. 2 Number and proportion of participants by SNP status during the study period  
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